Univariable competing risk regression models for LP
| Characteristic . | No. . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Age at VLDRT (y) | 299 | 1.01 | 0.99-1.02 | .5 |
| Sex | 299 | |||
| Male | — | — | ||
| Female | 0.89 | 0.57-1.37 | .6 | |
| Histology at VLDRT | 299 | |||
| FL | — | — | ||
| MZL | 0.65 | 0.39-1.11 | .12 | |
| Low-grade indolent | 0.80 | 0.32-1.97 | .6 | |
| Best overall response* | 235 | |||
| CR | — | — | ||
| PR, SD, or PD | 2.75 | 1.48-5.10 | .001 | |
| Maximum SUV before VLDRT | 251 | |||
| 0-5 | — | — | ||
| 5-7.5 | 0.82 | 0.36-1.84 | .6 | |
| 7.5-10 | 0.68 | 0.27-1.73 | .4 | |
| 10-15 | 1.59 | 0.78-3.24 | .2 | |
| ≥15 | 1.30 | 0.36-4.74 | .7 | |
| Unspecified but less than liver background | 0.73 | 0.28-1.88 | .5 | |
| Stage at VLDRT | 299 | |||
| Early | — | — | ||
| Advanced | 1.20 | 0.77-1.87 | .4 | |
| Nodal status | 299 | |||
| Nodal | — | — | ||
| Extranodal | 0.59 | 0.38-0.94 | .024 | |
| Both | 1.36 | 0.57-3.26 | .5 | |
| Site category | 299 | |||
| Cutaneous | — | — | ||
| Non-cutaneous | 1.29 | 0.69-2.40 | .4 | |
| Pre-VLDRT lesion size (cm) | 264 | |||
| 0-6 | — | — | ||
| ≥6 | 5.53 | 3.23-9.48 | <.001 | |
| Intent of VLDRT | 299 | |||
| Non-curable | — | — | ||
| Potentially curable | 0.30 | 0.12-0.73 | .008 | |
| Previous No. of lines of systemic therapy | 299 | |||
| 0 | — | — | ||
| 1 | 1.95 | 1.06-3.57 | .031 | |
| 2-4 | 2.23 | 1.29-3.84 | .004 | |
| > 4 | 3.73 | 1.47-9.47 | .006 | |
| Previous rituximab | 299 | 1.71 | 1.10-2.65 | .017 |
| Characteristic . | No. . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Age at VLDRT (y) | 299 | 1.01 | 0.99-1.02 | .5 |
| Sex | 299 | |||
| Male | — | — | ||
| Female | 0.89 | 0.57-1.37 | .6 | |
| Histology at VLDRT | 299 | |||
| FL | — | — | ||
| MZL | 0.65 | 0.39-1.11 | .12 | |
| Low-grade indolent | 0.80 | 0.32-1.97 | .6 | |
| Best overall response* | 235 | |||
| CR | — | — | ||
| PR, SD, or PD | 2.75 | 1.48-5.10 | .001 | |
| Maximum SUV before VLDRT | 251 | |||
| 0-5 | — | — | ||
| 5-7.5 | 0.82 | 0.36-1.84 | .6 | |
| 7.5-10 | 0.68 | 0.27-1.73 | .4 | |
| 10-15 | 1.59 | 0.78-3.24 | .2 | |
| ≥15 | 1.30 | 0.36-4.74 | .7 | |
| Unspecified but less than liver background | 0.73 | 0.28-1.88 | .5 | |
| Stage at VLDRT | 299 | |||
| Early | — | — | ||
| Advanced | 1.20 | 0.77-1.87 | .4 | |
| Nodal status | 299 | |||
| Nodal | — | — | ||
| Extranodal | 0.59 | 0.38-0.94 | .024 | |
| Both | 1.36 | 0.57-3.26 | .5 | |
| Site category | 299 | |||
| Cutaneous | — | — | ||
| Non-cutaneous | 1.29 | 0.69-2.40 | .4 | |
| Pre-VLDRT lesion size (cm) | 264 | |||
| 0-6 | — | — | ||
| ≥6 | 5.53 | 3.23-9.48 | <.001 | |
| Intent of VLDRT | 299 | |||
| Non-curable | — | — | ||
| Potentially curable | 0.30 | 0.12-0.73 | .008 | |
| Previous No. of lines of systemic therapy | 299 | |||
| 0 | — | — | ||
| 1 | 1.95 | 1.06-3.57 | .031 | |
| 2-4 | 2.23 | 1.29-3.84 | .004 | |
| > 4 | 3.73 | 1.47-9.47 | .006 | |
| Previous rituximab | 299 | 1.71 | 1.10-2.65 | .017 |
Given the variability in time of best response assessment, this factor was assessed using a landmark analysis with landmark time at 6 months after VLDRT.